Vima Doses First Patient in Parkinson's Tremor Trial
Vima Therapeutics begins its Phase 2 Vista PD study of VIM0423 for tremor that current Parkinson's treatments do not adequately control.
Updated on Nov. 5, 2026 in Alzheimer’s
Vima Therapeutics has dosed the first participant in its Phase 2 Vista PD trial of VIM0423, a once-daily oral treatment for tremor insufficiently responsive to dopaminergic therapy in adults with Parkinson's disease. The company also received a grant from The Michael J. Fox Foundation to support continued clinical development.
Why it matters
Parkinson's disease affects more than one million people in the United States, and roughly one-third continue to have tremor not adequately controlled by current therapies. No approved treatment specifically targets Parkinson's tremor, so the trial addresses an unmet need for patients and the Cambridge-based company's pipeline.
More than one million people in the United States live with Parkinson's disease, and about one-third continue to experience tremor not adequately controlled by existing therapies. Efficacy and safety results for VIM0423 in this population are not yet available, with topline Phase 2 data anticipated in the second half of 2027.
The players
Vima Therapeutics
Vima Therapeutics is a Cambridge, Massachusetts-based biopharmaceutical company developing VIM0423 for neurological movement disorders.
The Michael J. Fox Foundation
The Michael J. Fox Foundation is a major nonprofit that funds Parkinson's research and supports promising therapies through its Therapeutics Pipeline Program.
The details
Vima Therapeutics dosed the first participant in the Vista PD trial, which evaluates efficacy, pharmacokinetics, safety, and tolerability of VIM0423. VIM0423 is designed to selectively target muscarinic cholinergic receptors in the brain and is also in a Phase 2 study for isolated dystonia, which holds FDA Fast Track designation.
Timeline
November 5, 2026: First participant dosed in the Vista PD trial and Michael J. Fox Foundation support announced.
Second half of 2027: Topline data from the Phase 2 Parkinson's tremor and isolated dystonia trials anticipated.
Health Landscape
The Michael J. Fox Foundation's Therapeutics Pipeline Program funds candidate drugs aimed at unmet Parkinson's needs, and this grant supports Vima's effort to address tremor that current therapies leave uncontrolled. The trial adds a symptom-directed candidate to a field where most approved treatments focus on dopamine replacement.
People with Parkinson's whose tremor persists despite current medications may eventually have a new option if VIM0423 proves effective and safe. Patients interested in participating should check trial eligibility through the registry, as the study is still enrolling.
The takeaway
Tremor that persists despite standard Parkinson's medication is a recognized unmet need, and this trial directly targets it. Readers following the condition can watch for the 2027 topline results that will show whether the approach works.
What happens next
Topline data from Vima's Phase 2 trials in Parkinson's disease tremor and isolated dystonia are anticipated in the second half of 2027.
Further reading
For related coverage of neurodegenerative research, see Alzheimer's news from Cambridge.
More information
Details on enrollment and study design are listed in the Vista PD clinical trial registry entry (NCT07804615).
Source note: This article includes information reported by The Manila times.
